ecrin-mdr-crcClinical2022IPD Sharing (as of September 2023): NoColorectal CancerColorectal NeoplasmsRAS wild-type colorectal cancerCáncer colorrectal RAS nativoRas Wild-type Colorectal CancerColorectal CancerColorectal NeoplasmsCáncer Colorrectal Ras NativoInterventionalhttps://newmdr.ecrin.org/Study/106BelgiumCzechiaItalyFranceSpain12AURELIO-05SOT101CetuximabNanrilkefusp alfaSO-C101ECRIN MDRRecruitingfalseA Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal CancerThe primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa (SOT101) in combination with cetuximab in RAS wild-type colorectal cancer.2022-12-15106NCT056191722022-001527-32